Literature DB >> 10722716

The effect of a reducing-end extension on pentasaccharide binding by antithrombin.

K J Belzar1, T R Dafforn, M Petitou, R W Carrell, J A Huntington.   

Abstract

Antithrombin requires heparin for efficient inhibition of the final two proteinases of the blood coagulation cascade, factor Xa and thrombin. Antithrombin binds heparin via a specific pentasaccharide domain in a two-step mechanism whereby initial weak binding is followed by a conformational change and subsequent tight binding. The goal of this study is to investigate the role of a reducing-end extension in the binding of the longer oligosaccharides that contain the cognate pentasaccharide sequence. We determined the antithrombin binding properties of a synthetic heptasaccharide containing the natural pentasaccharide sequence (DEFGH) and an additional reducing-end disaccharide (DEFGHG'H'). Binding at low ionic strength is unaffected by the disaccharide addition, but at ionic strengths >/=0.2 the mode of heptasaccharide binding changes resulting in a 2-fold increase in affinity due to a decrease in the off-rate caused by a greater nonionic contribution to binding. Molecular modeling of possible binding modes for the heptasaccharide at high ionic strength indicates a possible shift in position of the pentasaccharide domain to occupy the extended heparin-binding site. This conclusion supports the likely presence of a range of sequences that can bind to and activate antithrombin in the natural heparan sulfates that line the vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722716     DOI: 10.1074/jbc.275.12.8733

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s).

Authors:  Arjun Raghuraman; Philip D Mosier; Umesh R Desai
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

2.  Conformational transitions induced in heparin octasaccharides by binding with antithrombin III.

Authors:  Marco Guerrini; Sara Guglieri; Daniela Beccati; Giangiacomo Torri; Christian Viskov; Pierre Mourier
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

3.  Antithrombin-binding oligosaccharides: structural diversities in a unique function?

Authors:  Marco Guerrini; Pierre A J Mourier; Giangiacomo Torri; Christian Viskov
Journal:  Glycoconj J       Date:  2014-10       Impact factor: 2.916

4.  Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III.

Authors:  Daniel C Pimenta; Iseli L Nantes; Eduardo S de Souza; Bernard Le Bonniec; Amando S Ito; Ivarne L S Tersariol; Vitor Oliveira; Maria A Juliano; Luiz Juliano
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

5.  Toward a robust computational screening strategy for identifying glycosaminoglycan sequences that display high specificity for target proteins.

Authors:  Nehru Viji Sankaranarayanan; Umesh R Desai
Journal:  Glycobiology       Date:  2014-07-21       Impact factor: 4.313

6.  Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue.

Authors:  Marco Guerrini; Sara Guglieri; Benito Casu; Giangiacomo Torri; Pierre Mourier; Christian Boudier; Christian Viskov
Journal:  J Biol Chem       Date:  2008-07-17       Impact factor: 5.157

7.  Inactive mutants of human pyridoxine 5'-phosphate oxidase: a possible role for a noncatalytic pyridoxal 5'-phosphate tight binding site.

Authors:  Mohini S Ghatge; Sayali S Karve; Tanya M S David; Mostafa H Ahmed; Faik N Musayev; Kendra Cunningham; Verne Schirch; Martin K Safo
Journal:  FEBS Open Bio       Date:  2016-03-22       Impact factor: 2.693

Review 8.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.